Photodynamic therapy for acute central serous chorioretinopathy: the safe effective lowest dose of verteporfin.

Purpose: To find the lowest effective dose of verteporfin in the treatment of acute central serous chorioretinopathy with photodynamic therapy (PDT).

Methods: Patients with acute central serous chorioretinopathy were chosen and treated with PDT with verteporfin. Decreasing doses of verteporfin were applied to the first 7 patients at 70%, 60%, 50%, 40%, 30%, 20%, and 10% of the full dose (6 mg/m).